

Ticker Symbol: CEMI
www.chembio.com

Business Summary & Investment Highlights


Chembio Diagnostics, Inc. (Chembio), through its wholly owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio's core business of rapid HIV tests.

- >33% Five Year Revenue CAGR during which operating performance improved continuously.
- Consecutive record revenues and profits in 2009 and 2010.
- Strategy is to create core business of public health and women's health products to be complemented by OEM and selected out-licensing opportunities. Robust pipeline of POCT products for HIV (oral fluid), Syphilis, Influenza, Hepatitis-C and other infectious diseases based on Chembio's patented DPP® technology. Seven products developed on DPP® platform including three (HIV, Syphilis and Influenza) that are or will be undergoing US FDA regulatory evaluations/ submissions in 2011-2012.
- Significant income from research contracts and grants, including two, \$3MM, three year Phase II United States National Institutes of Health grants; one awarded in 2009 and one awarded March, 2011.

Selected Financial Information

Stock Information

Ticker Symbol	CEMI
Price 2/28/11	\$0.420
52 Week High	\$0.490
52 Week Low	\$0.159
Outstanding Shares (MM)	62.2
Market Capitalization (MM)	\$26.1
Fully Diluted (FD) Shares	70.5
Management Holding-FD	11.1
Average Volume (3 Mos)	45,000



Major Beneficial Holders

Beneficial Shares Owned (MM)

Lawrence Siebert	6.9
Inverness Medical Innovations, Inc.	5.4
Crestview Capital Offshore Fund, Inc.	3.4

Balance Sheet Data (\$000s)

Dec. '10 Dec. '09

Cash	\$2,136	\$1,068
Accts. Receivable	3,947	1,776
Inventories	1,349	1,556
Other Current Assets	205	267
Total Current Assets	7,637	4,667
Net Fixed Assets	813	580
Other Assets	636	1,068
Total Assets	9,086	6,315
Total Current Liab.	3,076	3,173
Total Other Liab.	201	54
Total Liabilities	3,277	3,227
Total Equity	5,809	3,088
Total Liabilities & Shareholders Equity	\$ 9,086	\$ 6,315

Selected Comparative Historical Financial Data

(\$000s)	For the Years Ended					
	2010	2009	2008	2007	2006	2005
Total Revenues	\$16,705	\$13,834	\$11,050	\$9,231	\$6,503	\$3,941
Cost of sales	8,604	7,974	7,198	6,435	4,894	2,996
Gross Profit	8,101	5,860	3,852	2,796	1,609	945
	48.5%	42.4%	34.9%	30.3%	24.7%	24.0%
R&D Expense	2,586	2,884	2,605	1,907	1,402	1,365
SG&A Expense	2,941	2,659	3,317	3,765	4,787	2,878
Operating Income (Loss)	2,574	317	(2,071)	(2,876)	(4,580)	(3,298)
Other Inc. (Expense)	(15)	(8)	122	249	(415)	46
Net Income (Loss) - Stkholders	2,559	309	(1,949)	(2,627)	(4,995)	(3,252)
Net Income (Loss)	\$2,513	\$309	(\$1,949)	(\$8,272)	(\$8,205)	(\$6,769)
Net Income (Loss) - per Share	\$0.04	\$0.00	(\$0.03)	(\$0.57)	(\$0.80)	(\$0.88)
Avg. No. Shares (Millions)	62.103	61.946	61.267	14.608	10.293	7.705
Working capital	4,560	1,494	1,664	3,229	5,113	831
Total assets	9,086	6,315	5,915	6,585	7,907	3,016
Total liabilities	3,277	3,227	3,338	2,322	2,297	1,964
Equity (Deficit)	5,809	3,088	2,577	4,263	(940)	1,053

Chembio Diagnostics, Inc.

3661 Horseblock Road
Medford, NY 11763
Ph. 631-924-1135
Fax 631-924-2065
www.chembio.com

Investor Relations

The Investor Relations Group
James Carbonara JCarbonara@investorrelationsgroup.com
212-825-3210

Company Contact

Susan Norcott
631-924-1135 x125
SNorcott@chembio.com





Chembio's Dual Path Platform (DPP®)
Patented in 2007

DPP® Technology

Competitive Advantages For POC Testing

- **Improved Sensitivity** - enabled by more efficient binding method
- **Easier Multiplexing** - due to even and direct distribution of sample to multiple test lines
- **Enhanced Sample Control** - as result of independent sample migration path
- **Clearer Results** - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results



Chembio's Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.



Senior Management Team

Lawrence A. Siebert, Chairman & CEO, 25 years of management and financing experience

Richard J. Larkin, CFO, 25 years of operational and financial experience

Javan Esfandiari, SVP R&D, 15 years of experience in development of in-vitro point of care products

Board of Directors

Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, INC. (NYSE:CMI)

Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development

